Posted by Michael Wonder on 08 Oct 2025
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma
8 October 2025 - Today, the FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
Efficacy was evaluated in C-POST, a randomised, double-blind, multi-centre, placebo-controlled trial in 415 patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
